Botanix Pharmaceuticals secures A$45 million capital raise to strengthen its pharmaceutical operations. The funding will primarily support API supply chain diversification and Sofdra product growth. By establishing an alternate API supplier by 2028, the company aims to reduce cost of goods sold by 25-40%. Sofdra, their lead product, has already demonstrated promising commercial traction with Q2 FY26 revenue of A$9.1 million and a 24% quarterly prescription increase. Market research indicates strong future potential, with 90% of healthcare professionals expecting to increase Sofdra prescriptions. The capital raise includes a two-tranche placement at A$0.06 per share and an underwritten security purchase plan. Directors and CEO are personally investing approximately A$500,000, signaling confidence in the company's strategic direction and growth potential.
